Claudia Chiodoni

Via Venezian 1
Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 01, 2026

The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations.

The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations.

Journal: Tumori

Published: August 09, 2025

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 29, 2025

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 12, 2025

Neutrophil extracellular traps in cancer: immune modulation, therapy resistance, and the dilemma of targeting.

Neutrophil extracellular traps in cancer: immune modulation, therapy resistance, and the dilemma of targeting.

Journal: Cell death & disease

Published: February 14, 2025

The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial.

The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 13, 2024

Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.

Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.

Journal: Cell death & disease

Published: May 28, 2024

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 27, 2024

Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.

Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.

Journal: Cancer immunology research

Published: September 25, 2023

ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion.

ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion.

Journal: Cell reports

Published: March 21, 2023

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 07, 2023

Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement.

Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement.

Journal: Expert review of anticancer therapy

Published: February 21, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026